TABLE 116Resultsa,b of the deterministic base-case incremental CUA for people with mild-to-moderate AD (MMSE 26–10)

TreatmentMean months to institutional carecMonths' delay to institutional care compared with BSCTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICERa,b (£)
Galantamine (16–24 mg)30.41.669,5921.617
Rivastigmine patch (9.5 mg/day)30.31.569,5981.616Dominated
Donepezil (10 mg)30.51.769,6241.619320.00217,900
Rivastigmine capsules (9–12 mg)30.21.469,6781.613Dominated
BSC28.8NA70,2121.584Dominated

NA, not applicable.

a

Cost per QALY rounded to the nearest £100.

b

Each technology is compared with the next cheapest non-dominated technology.

c

This compares with a mean time to end of pre-institutionalisation for all 92 participants in the study by Wolstenholme and colleagues196 of 30 months. This difference arises from the Wolstenholme and colleagues'196 IPD containing all severities of AD, not just those who are mild to moderate as in the above table.

From: 6, The Peninsula Technology Assessment Group cost–utility assessment

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.